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Adenosine A2A receptors seem to exist in typical (more in striatum) and atypical (more in 
hippocampus and cortex) subtypes. In the present study, we investigated the affinity of two 
adenosine A2A receptor antagonists, ST1535 [2 butyl -9-methyl-8-(2H-1,2,3-triazol 2-yl)-9H-
purin-6-xylamine] and KW6002 [(E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7-dihydro-
1H-purine-2,6,dione] to the “typical” and “atypical” A2A binding sites. Affinity was determined 
by radioligand competition experiments in membranes from rat striatum and hippocampus. 
Displacement of the adenosine analog [3H]CGS21680 [2-p-(2-carboxyethyl)phenethyl-amino-
5’-N-ethylcarbox-amidoadenosine] was evaluated in the absence or in the presence of either 
CSC [8-(3-chlorostyryl)-caffeine], an adenosine A2A antagonist that pharmacologically isolates 
atypical binding sites, or DPCPX (8-cyclopentyl-1,3-dipropylxanthine), an adenosine A1 receptor 
antagonist that pharmacologically isolates typical binding site. ZM241385 [84-(2-[7-amino-2-
(2-furyl) [1,2,4]-triazol[2,3-a][1,3,5]triazin-5-yl amino]ethyl) phenol)] and SCH58261 [(5-amino-7-
(β-phenylethyl)-2-(8-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c) pyrimidine], two other adenosine 
A2A receptor antagonists, which were reported to differently bind to atypical and typical A2A 
receptors, were used as reference compounds. ST1535, KW6002, ZM241385 and SCH58261 
displaced [3H]CGS21680 with higher affinity in striatum than in hippocampus. In hippocampus, 
no typical adenosine A2A binding was detected, and ST1535 was the only compound that 
occupied atypical A2A adenosine receptors. Present data are explained in terms of heteromeric 
association among adenosine A2A, A2B and A1 receptors, rather than with the presence of atypical 
A2A receptor subtype.
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receptors. The second high-affinity binding site predominates in 
the cortex and hippocampus, and has binding characteristics inter-
mediary between those of A1 and A2A receptors (Wan et al., 1990; 
Johansson et al., 1993; Kirk and Richardson, 1995; Cunha et al., 
1996). These pharmacologically distinct binding sites were referred 
as “typical”, i.e., striatal-like, also present with low abundance in 
the cortex and hippocampus, and “atypical”, predominant in the 
cortex and hippocampus. The greatest pharmacological differ-
ences between the [3H]CGS21680 binding to “typical” and “atypi-
cal” binding sites were observed with the selective A2A antagonists 
KF17837 (Nonaka et al., 1994) and CSC (Jacobson et al., 1993) and 
the selective A1 antagonist DPCPX (Lohse et al., 1987). KF17837, 
which is 62-fold A2A/A1 selective, and CSC which is 520-fold A2A/
A1 selective, inhibited most of the [3H]CGS21680 binding to stri-
atal membranes, but they were 10-fold less potent in inhibiting 
most of the [3H]CGS21680 binding in the hippocampus and cor-
tex. On the contrary, in the hippocampus and cortex, but not in 
the striatum, most of the [3H]CGS21680 binding was displaced 
by DPCPX at low nanomolar concentrations (Cunha et al., 1996, 
1997). This distinct pharmacological affinity profile, even though 
the high selectivity of [3H]CGS21680 for A2A receptors, has raised 
reasonable doubts as whether these atypical binding sites might 
represent A2A receptors.
IntroductIon
Adenosine represents an endogenous inhibitory modulator widely 
distributed in the central nervous system, exerting its physiologi-
cal actions through activation of four structurally distinct surface 
receptors (A1, A2A, A2B and A3), all of which represent attractive 
targets for several human diseases (Fredholm et al., 2001; Sebastião 
and Ribeiro, 2009). Some A2A antagonists are currently studied 
for their role in controlling motor function and as potential neu-
roprotective agents in Parkinson’s disease (Ikeda et al., 2002; Yu 
et al., 2008; Morelli et al., 2009; Pinna, 2009). A role for adenosine 
A2A receptors was also suggested in drug addiction (Ferré et al., 
2007) and sensitization (Bastia et al., 2005), narcolepsy and pain 
(Ferré et al., 2007), and respiration in immature animals (Mayer 
et al., 2005).
Characterization of adenosine receptor subtypes are tradition-
ally made by the means of specific pharmacological tools (Fredholm 
et al., 2001). Among these, CGS21680 (Wan et al., 1990) is widely 
used to study the A2A receptor subtype. It has Ki values for adeno-
sine A2A and A1 receptors of about 22 and 3,100 nM, respectively 
(Hutchison et al., 1989). [3H]CGS21680 was also used to character-
ize two high-affinity binding sites in cortical, hippocampal and stri-
atal membranes. The first high-affinity binding site predominates 
in the striatum and has binding characteristics compatible with A2A 
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membrane suspension incubated with 5 U/ml adenosine deaminase 
(ADA, Sigma-Aldrich) for 30 min at 37°C to remove endogenous 
adenosine. The protein concentration of membrane suspension was 
determined using the Bradford method (Pierce, Rockford, IL, USA) 
with bovine albumin as standard. Competition binding experiments 
with  [3H]CGS21680  were  performed  by  incubating  membranes 
(50–100 μg of protein/sample) with a single concentrations of [3H]
CGS21680 (30 nM) for 2 h at room temperature in a solution con-
taining 50 mM Tris-HCl, pH 7.4, 10 mM MgCl2 and 5 U/ml ADA 
and various concentrations (ranging from 10−5 to 10−12 M) of test 
compounds. Non-specific binding was determined in the presence 
of an excess of cold 2-chloroadenosine (Sigma-Aldrich). The binding 
reactions were stopped by vacuum filtration through GF/B filters, 
followed by washing of the filters with ice-cold washing buffer (same 
composition as the binding buffer) and filter-bound radioactivity 
measured by scintillation spectrometry. Competition studies were 
performed with the various compounds alone or in the presence 
of an excess of either CSC or DPCPX (both from Sigma-Aldrich). 
The compounds were dissolved in 100% DMSO (Sigma-Aldrich) 
at a concentration of 10 mM and stored at −20°C. An intermediate 
100 μM working solution was prepared in water and subsequent 
scalar working solutions in incubation buffer.
data evaluatIon
Concentration-response binding curves obtained for every test com-
pound (n = 3–4) were analyzed together using non-linear regression 
with GraphPad PRISM commercial software and expressed as IC50 
(concentration of compounds that inhibits 50% of specific radio-
ligand binding) and 95% confidence intervals. Inhibitory binding 
constant (Ki) values were calculated from IC50 values according 
to the Cheng and Prusoff equation Ki = IC50/(1 + [C]/Kd), where 
[C] is the concentration of the radioligand and Kd its dissociation 
constant. Kd of 62 nM and 12 nM were used for hippocampus and 
striatum, respectively, as reported by Cunha et al. (1996).
results
Binding experiments were performed using in both brain tissues a 
radioligand concentration of 30 nM, which is intermediate between 
its Kd values in the striatum and hippocampus, respectively (Cunha 
et al., 1996). In addition, to exclude the role of different endog-
enous adenosine concentrations in the tissues, experiments were 
performed after a 30 min treatment with 5 U/ml ADA.
In  such  conditions,  [3H]CGS21680  specific  binding  in  the 
striatum represented about 80% of the total binding. All com-
pounds bound to adenosine A2A receptors in the striatum both in 
the absence and in the presence of either CSC or DPCPX, which 
were supposed to isolate “atypical” and “typical” receptor subtypes, 
respectively (Cunha et al., 1996) (Table 1, Figures 1, 3 and 4).
In  the  striatum,  the  affinity  values  of  both  ST1535  and 
KW6002 for “total” and “typical” A2A receptors were similar and 
decreased from two to five fold for “atypical” binding sites (Table 1, 
Figures 1, 3 and 4). ZM241385 and SCH58261 displaced [3H]
CGS21680 binding to “total” A2A receptors with affinities compa-
rable to those previously published (Table 1, Figure 1). However, 
isolation of ”typical” binding site (Table 1, Figure 3) determined 
a 10-fold decrease in the affinity of ZM241385, a result in contrast 
with the literature (Cunha et al., 1996).
ST1535 and KW6002 are two known A2A receptor antagonists, 
proposed for the treatment of Parkinson’s disease (Kase et al., 2003; 
Pinna, 2009), which differentiate for their in vitro selectivity pro-
file on adenosine receptors. ST1535 has a preferential antagonistic 
activity on A2A receptors, but it is also an antagonist on A1 recep-
tors (Stasi et al., 2006). On the other hand, KW6002 also binds to 
adenosine A2B receptors (Stasi et al., 2006).
Present work was aimed at determining ST1535 and KW6002 
affinities toward the adenosine A2A receptor subtypes in two rat 
brain regions, striatum and hippocampus.
ST1535 and KW6002-mediated displacement of [3H]CGS21680 
binding was evaluated in the absence or in the presence of either 
CSC, which pharmacologically isolates atypical CGS21680 bind-
ing  sites,  or  DPCPX,  which  pharmacologically  isolates  typical 
CGS21680 binding site (Cunha et al., 1996). ZM241385, an ade-
nosine A2A receptor antagonist with equal potency to display [3H]
CGS21680 binding in striatal and limbic regions (Cunha et al., 
1997), and SCH21680, an adenosine A2A receptor antagonist that 
clearly discriminates between the two different binding sites in 
different brain regions (Lindström et al., 1996), were used as refer-
ence compounds.
MaterIals and Methods
sources of coMpounds
ST1535,  KW6002  and  SCH58261  were  supplied  by  sigma-tau 
Chemical  Department.  CSC  [8-(3-chlorostyryl)  caffeine]  and 
DPCPX  [8-cyclopentyl-1,3-dipropylxantine]  were  purchased 
from  Sigma-Aldrich  (Sigma-Aldrich,  St.  Louis,  MO,  USA), 
while  ZM241385  was  obtained  from  Tocris  (Tocris,  Ellisville, 
MI, USA).
anIMal husbandry
Six male Wistar rats, 11- to 12-week old (Harlan, S. Pietro al 
Natisone, Udine, Italy) were used. Rats were housed in makro-
lon cages (Tecniplast Gazzada 42.5 cm × 26.6 cm × 18 cm height) 
(three rats/cage) with stainless steel covered feed racks and steri-
lized, dust-free bedding cobs. Animals were housed under a light-
dark cycle, with constant temperature and humidity. Parameters of 
the animal rooms were as follows: temperature 22 ± 2°C, relative 
humidity 55 ± 10%, about 15–20 filtered air exchanges/hour and 
a 12-h circadian cycle of artificial light (7 a.m.–7 p.m.). A diet (in 
pellets) coded GLP 4RF 21, produced by Mucedola S.r.l. of Settimo 
Milanese (a licensee of Charles River – Italia S.p.A.), was used. All 
parts of the study concerning animal care were performed under 
the control of sigma-tau veterinarians, in compliance with Italian 
regulatory system (D.L.vo 116 of 27 January 1992, art. 6). Animals 
were sacrificed by beheading and striatum and hippocampus were 
collected and stored at −80°C.
MeMbrane preparatIon and coMpetItIon bIndIng
The collected tissues were homogenized in about 25 volumes of incu-
bation buffer and centrifuged at 40,000 g for 10 min at 4°C. The pellet 
was resuspended in the same fresh buffer, homogenized, centrifuged 
once again and the final pellet stored at −80°C until use. The meth-
ods used for binding studies were as those described by Cunha et al. 
(1996). Prior to the competition binding assay, the pellet was resus-
pended in appropriate buffer at the wanted protein concentration and www.frontiersin.org  August 2010  | Volume 1  | Article 22  |  3
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obtained in hippocampus with the use of DPCPX were not evalu-
able (Table 2). In the presence of CSC, ST1535 was the only com-
pound which displaced some affinity, while no binding of KW6002 
and ZM241385 was observable. For ZM241385 and SCH58261, cal-
culation of IC50 in the hippocampus was possible only by imposing 
a slope equal to 1, while ST1535 and KW6002 had Hill coefficients 
around 0.6–0.8 (Figures 2 and 5).
dIscussIon
All compounds bound better to A2A in the striatum than in hip-
pocampus, confirming some published data in literature (Wan 
et al., 1990; Johansson et al., 1993; Kirk and Richardson, 1995; 
Cunha et al., 1996). As repeatedly shown, using different methods, 
adenosine A2A receptors are highly enriched in caudate putamen, 
nucleus accumbens and tuberculum olfactorium, and expression 
levels elsewhere are lower (Jarvis and Williams, 1989; Dixon et al., 
1996). However, it seems conceivable that differences in affinity 
values might not be due to different number of adenosine A2A 
receptors in the two tissues, since the ratio between the affinity 
values in hippocampus and striatum was not a constant but variable 
among the different compounds we used. In fact, if one could have 
hypothesized that the small difference in affinity values for ST1535 
(about 5-fold) and KW6002 (about 10-fold) between striatum and 
hippocampus could have been attributed to a different number of 
receptors, the same hypothesis cannot explain the greater difference 
in affinity values for ZM241385 (about 1100-fold) and SCH58261 
(about 200-fold). The affinity values of the various compounds 
for total adenosine A2A   striatal receptors are in agreement with 
The  lowest  Hill  coefficients,  around  0.6,  were  found  for 
ZM241385 in binding to “total” and “atypical” striatal adenos-
ine A2A receptors (Figures 1 and 4). Hill coefficients for ST1535 
were around the unit in binding “typical” and “atypical” recep-
tors and 0.7 for “total” receptors (Figures 1, 3 and 4). Hill coef-
ficients for KW6002 in binding “atypical” receptors were 1.4, 
and  0.7–0.8  for  “total”  and  “typical”  receptors,  respectively 
(Figures 1, 3 and 4).
In hippocampus, [3H]CGS21680 specific binding represented 
about 50% of the total binding. All compounds bound to “total” 
adenosine A2A receptors (Table 2, Figure 2) with affinity values lower 
than in the striatum. In the hippocampus, the use of DPCPX com-
pletely abolished [3H]CGS21680 specific binding, possibly because 
of saturation of all binding sites by DPCPX. As a   consequence, data 
Table 1 | Displacement of [3H]CGS 21680 binding from total, typical and 
atypical adenosine A2A receptors in rat striatal membranes.
Compound  Ki values (nM) in striatum
  Total  Typical  Atypical
ST1535  22.8 (18.4–28.1)  33.7 (25–45.5)  73.0 (62.5–85.4)
KW6002  23.0 (17.2–30.7)  13.3 (5.5–32.2)  74.2 (55.2–99.7)
ZM58261  0.7 (0.6–0.9)  8.2 (5.8–11.8)  2.5 (1.4–4.3)
SCH58261  4.8 (3.8–6.0)  Not evaluated  Not evaluated
Values  are  mean  with  95%  confidence  intervals  (in  brackets)  of  3–4 
experiments.
FiGure 1 | Dose–response curves of compound-mediated displacement of 
[3H]CGS21680 binding to rat striatum. The ordinates represent the specific 
binding of 30 nmol/L [3H]CGS21680 in the presence of different concentrations 
of compounds. Non-specific binding was determined with 100 μM 
2-chloroadenosine. Curves were obtained from 3 to 4 independent experiments 
performed in duplicate. Values in brackets represent 95% confidence intervals.Frontiers in Psychiatry  |  Psychopharmacology    August 2010  | Volume 1  | Article 22  |  4
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FiGure 2 | Dose–response curves of compound-mediated displacement of 
[3H]CGS21680 binding to rat striatum in the presence of 100 nmol/L 
DPCPX, to isolate typical adenosine A2A receptors. The ordinates represent 
the specific binding of 30 nmol/L [3H]CGS21680 in the presence of different 
concentrations of compounds and a fixed saturating concentration of DPCPX. 
Non-specific binding was determined with 100 μM 2-chloroadenosine. Curves 
were obtained from three independent experiments performed in duplicate. 
Values in brackets represent 95% confidence intervals.
FiGure 3 | Dose–response curve of compound-mediated displacement of 
[3H]CGS21680 binding to rat striatum in the presence of 200 nmol/L CSC, 
to isolate atypical adenosine A2A receptors. The ordinates represent the 
specific binding of 30 nmol/L [3H]CGS21680 in the presence of different 
concentrations of compounds and a fixed saturating concentration of CSC. 
Non-specific binding was determined with 100 μM 2-chloroadenosine. Curves 
were obtained from three independent experiments performed in duplicate. 
Values in brackets represent 95% confidence intervals.www.frontiersin.org  August 2010  | Volume 1  | Article 22  |  5
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published data (Lindströom et al., 1996; Cunha et al., 1997; Ongini 
et al., 1999; Stasi et al., 2006; Yang et al., 2007; Pinna, 2009). Our 
results, however, are in contrast with ZM241385 binding data by 
Cunha et al. (1996), who did not show evident difference between 
striatal and hippocampal adenosine A2A receptors. On the contrary, 
we found that ZM241385 displayed over 1,000-fold affinity for 
A2A receptors in striatum compared to hippocampus. In addition, 
in striatum, ZM241385 also bound with higher affinity to “atypi-
cal” than to “typical” receptors, and did not recognize “atypical” 
receptors in the hippocampus, in contrast with Cunha et al. (1996). 
We can just hypothesize that these contrasting results with Cunha 
are  due  to  different  receptor  preparation  or  binding  methods 
or,   alternatively, with the use of different animal strain and age. 
FiGure 4 | Dose–response curves of compound-mediated displacement of 
[3H]CGS21680 binding to rat hippocampus. The ordinates represent the 
specific binding of 30 nmol/L [3H]CGS21680 in the presence of different 
concentrations of compounds. Non-specific binding was determined with 100 μM 
2-chloroadenosine. Curves were obtained from four independent experiments 
performed in duplicate. Values in brackets represent 95% confidence intervals.
Table 2 | Displacement of [3H]CGS 21680 binding from total, typical and 
atypical adenosine A2A receptors in rat hippocampal membranes.
Compound  Ki values (nM) in hippocampus
  Total  Typical  Atypical
ST1535  110 (60–202)  Not evaluable  146 (70–302)
KW6002  259 (168–400)  Not evaluable  Not evaluable
ZM58261  785 (435–1416)  Not evaluable  Not evaluable
SCH58261  1009 (532–1914)  Not evaluated  Not evaluated
Values  are  mean  with  95%  confidence  intervals  (in  brackets)  of  3–4 
experiments.
FiGure 5 | Dose–response curves of compound-mediated displacement 
of [3H]CGS21680 binding to rat hippocampus in the presence of 
200 nmol/L CSC, to isolate atypical adenosine A2A receptors. The ordinates 
represent the specific binding of 30 nmol/L [3H]CGS21680 in the presence of 
different concentrations of compounds and a fixed saturating concentration of 
CSC. Non-specific binding determined with 100 μM 2-chloroadenosine. The 
curve was obtained from three independent experiments performed in 
duplicate. Values in brackets represent 95% confidence intervals.
Similarly to ZM241385, KW6002 occupied “atypical” adenosine A2A 
receptors in striatum but not in hippocampus. Despite the evidence 
that [3H]CGS21680 displays different affinity values for adenosine 
A1 and A2A receptors (Hutchison et al., 1989), at the concentrations Frontiers in Psychiatry  |  Psychopharmacology    August 2010  | Volume 1  | Article 22  |  6
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